Opinion
Video
Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer
Panelists explore emerging combination therapies in maintenance treatment for advanced ovarian cancer, including rucaparib + nivolumab; atezolizumab + bevacizumab; and olaparib + cediranib, also discussing how these strategies fit into the current treatment paradigm and in which patient populations they may be considered.
Video content above is prompted by the following:
- Typically, how long do you keep patients on PARP inhibitors in first-line maintenance? What about second-line maintenance?
Related Videos
Related Content
